Back to all studies
CompletedNCT03775109

IL-1 Signal Inhibition in Alcoholic Hepatitis

This study is completed. It focuses on addiction and currently lists study information in the United Kingdom.

Addiction, Alcoholic HepatitisDrugOver 18 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Canakinumab 150mg/ml solution for injection may be useful for adults experiencing addiction.

What would participation involve?

Participants may receive Canakinumab 150mg/ml solution for injection, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United Kingdom.

Who is it mainly for?

This study appears to be mainly for adults with addiction.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: February 12, 2019
Recruitment status
Completed
Enrollment listed in the registry
55
Sponsor
Imperial College London
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United Kingdom
Age range
Over 18 Years
Official registry ID
NCT03775109
Official title
IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT03775109. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United Kingdom · 16 sites
  • University Hospitals Bristol NHS Foundation Trust
    Bristol
    Site status: Not listed — confirm with the team
  • Glasgow Royal Infirmary, Greater Glasgow & Clyde
    Glasgow
    Site status: Not listed — confirm with the team
  • Queen Elizabeth University Hospital
    Glasgow
    Site status: Not listed — confirm with the team
  • Leeds Teaching Hospitals NHS Trust
    Leeds
    Site status: Not listed — confirm with the team
  • Aintree University Hospital
    Liverpool
    Site status: Not listed — confirm with the team
  • Royal Liverpool and Broadgreen University Hospitals NHS Trust
    Liverpool
    Site status: Not listed — confirm with the team
  • Imperial College Healthcare NHS Foundation Trust
    London
    Site status: Not listed — confirm with the team
  • Chelsea and Westminster Hospital NHS Foundation Trust
    London
    Site status: Not listed — confirm with the team
  • King's College Hospital NHS Foundation Trust
    London
    Site status: Not listed — confirm with the team
  • Royal Free London NHS Foundation Trust
    London
    Site status: Not listed — confirm with the team
  • St George's University Hospitals NHS Foundation Trust
    London
    Site status: Not listed — confirm with the team
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne
    Site status: Not listed — confirm with the team
  • Nottingham University Hospitals NHS Trust
    Nottingham
    Site status: Not listed — confirm with the team
  • John Radcliffe Hospital, Oxford University NHS Foundation Trust
    Oxford
    Site status: Not listed — confirm with the team
  • Plymouth Hospitals NHS Trust
    Plymouth
    Site status: Not listed — confirm with the team
  • University Hospital Southampton NHS Foundation Trust
    Southampton
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with addiction. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Canakinumab 150mg/ml solution for injection, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Are there criteria about substance use or wanting to reduce it?

The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Imperial College London, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me